gadobenate
Trade name: Multihance
Small moleculeapproved
Approved
Nov 23, 2004
Gadobenic acid is a complex of gadolinium with the ligand BOPTA. In the form of the methylglucamine salt meglumine gadobenate (INNm) or gadobenate dimeglumine (USAN), it is used as a gadolinium-based MRI contrast medium. — Wikipedia
Clinical trial activity
24 trials · 16 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
10
Phase 3
6
Phase 4
6
Earliest trial started Apr 1, 2006 (NCT00323310)
Timeline
Indications
Approved for
Studied for
- Aortic Diseases · Phase 3
- Arterial Occlusive Diseases · Phase 3
- Brain Diseases · Phase 4
- Brain Neoplasms · Phase 4
- Breast Neoplasms · Phase 3
- Carcinoma, Intraductal, Noninfiltrating · Phase 2
- Central Nervous System Diseases · Phase 3
- Cognition · Phase 4
- Colorectal Neoplasms · Phase 4
- Contrast Media · Phase 4
- Glioma · Early Phase 1
- Heart Defects, Congenital · Phase 3
- Heart Failure · Early Phase 1
- Hypertrophy, Left Ventricular · Early Phase 1
- Lymphoma · Early Phase 1
- Motor Activity · Phase 4
- Myocardial Infarction · Early Phase 1
- Neoplasm Metastasis · Phase 4
- Peripheral Vascular Diseases · Phase 3
- Prostatic Neoplasms · Phase 2
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedNov 23, 2004
Chemistry & pharmacology
- Mol. weight
- 862.94 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaGadobenic acid ↗
- ChEMBLCHEMBL1200571 ↗
Also known as
- 3,6,9-triaza-12-oxa-3,6,9-tricarboxymethylene-10-carboxy-13-phenyltridecanoic acid, gadolinium
- acide gadobenique
- acide gadobenique
- acido gadobenico
- acido gadobenico
- acidum gadobenicum
- acidum gadobenicum
- altana pharma brand of gadobenic acid, dimeglumine salt
- b 19036
- b-19036
- b1903617
- gadobenate
- gadobenate
- gadobenate dimeglumine
- gadobenate dimeglumine
- gadobenate dimeglumine
- gadobenate dimeglumine
- gadobenate dimeglumine
- gadobenate dimeglumine
- gadobenate dimeglumine
- gadobenic acid
- gadobenic acid
- gadobenic acid
- gadobenic acid
- gadobenic acid
- gadobenic acid
- gadobenic acid
- gadobenic acid, dimeglumine salt
- gadobensäure
- gadobensäure
- gadolinium-benzyloxypropionyl tetraacetate
- gadolinium-bopta-dimeg
- gd-bopta
- gd(bopta)2
- multihance
- multihance
- multihance
- multihance
- multihance
- multihance
- multihance multipack
- multihance multipack
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06406517 | Phase 3 | May 31, 2024 | Bracco, University of California, San Diego |
| NCT06086704 | Phase 2 | Jan 31, 2024 | National Cancer Institute (NCI), University of Wisconsin |
| NCT04973007 | Phase 4 | Jun 22, 2021 | Bracco, National Cancer Institute (NCI), University of Colorado, Denver |
| NCT04910425 | Phase 2 | Jun 17, 2021 | National Cancer Institute (NCI), Northwestern University |
| NCT04373564 | Phase 4 | Jul 1, 2020 | Bayer, Bracco, General Electric, Guerbet, IQVIA |
| NCT04132843 | Early Phase 1 (Phase 1) | Jan 31, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03703492 | Phase 2 | Nov 12, 2018 | National Cancer Institute (NCI), University of Wisconsin |
| NCT02973633 | Early Phase 1 (Phase 1) | Jun 30, 2017 | Harvard University |
| NCT03091803 | N/A | Apr 4, 2017 | National Cancer Institute (NCI), University of Southern California |
| NCT02633501 | Phase 2 | Jun 1, 2016 | Guerbet |
| NCT02400840 | N/A | Jan 1, 2015 | Rouen Normandy University |
| NCT02070380 | Phase 4 | Feb 1, 2014 | Bracco |
| NCT01752231 | N/A | Nov 1, 2012 | City of Hope National Medical Center |
| NCT02967380 | N/A | Dec 14, 2011 | National Cancer Institute (NCI), University of Southern California |
| NCT00907530 | Phase 4 | Sep 1, 2009 | Bracco |
| NCT01260636 | Phase 3 | Sep 1, 2009 | Bracco |
| NCT00539253 | N/A | Sep 1, 2007 | Bracco, Johns Hopkins University |
| NCT00486473 | Phase 3 | Jul 1, 2007 | Bracco |
| NCT00408083 | Phase 3 | Dec 1, 2006 | Bracco |
| NCT00415805 | Phase 3 | Dec 1, 2006 | Bracco |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bracco | For profit | 14 | 10 | 4 | 2006 |
| National Cancer Institute (NCI) | Government | 7 | 0 | 4 | 2011 |
| Guerbet | For profit | 2 | 2 | 2 | 2016 |
| University of Southern California | Academic/Hospital | 2 | 2 | 1 | 2011 |
| University of Wisconsin | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Bayer | For profit | 1 | 0 | 1 | 2020 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2012 |
| General Electric | For profit | 1 | 0 | 1 | 2020 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| IQVIA | For profit | 1 | 0 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Rouen Normandy University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2020 |
16 organizations
Page 1 / 1